For 23 years, Medicare explicitly excluded weight loss medications from Part D coverage. That policy, established in 2003, persisted through the entire rise of GLP-1 medications — through Byetta's approval in 2005, through Saxenda in 2014, through Wegovy in 2021, and through the explosion of semaglutide and tirzepatide prescriptions that followed.
On July 1, 2026, that ban effectively ends.
What the Medicare GLP-1 Bridge Actually Is
The Medicare GLP-1 Bridge is a temporary demonstration program run by the Centers for Medicare & Medicaid Services (CMS). It provides eligible Medicare Part D beneficiaries with coverage of select GLP-1 medications for obesity from July 1, 2026 through December 31, 2027 — originally slated to end in December 2026 but extended by six months after the longer-term BALANCE Model was indefinitely delayed.
This is not standard Part D coverage. The Bridge is a separate pathway built on Section 402 authority, designed to fill the gap while CMS determines what permanent coverage should look like. But for the roughly 65 million Medicare beneficiaries in the U.S., the practical result is the same: access to GLP-1 weight loss medications at a predictable, capped cost.
The legislative foundation came from the Treat and Reduce Obesity Act (TROA), signed into law in late 2025, which expanded Medicare Part D to cover FDA-approved anti-obesity medications. Effective April 1, 2026, Part D plans were required to include at least one GLP-1 medication approved for chronic weight management on their formularies.
Which Medications Are Covered
The Bridge program covers FDA-approved anti-obesity medications, not off-label uses or compounded versions. As of the July 2026 launch, the covered GLP-1 medications are:
- Wegovy (semaglutide injection) — including the new Wegovy HD 7.2mg dose approved March 2026
- Oral Wegovy (semaglutide 25mg daily pill)
- Zepbound (tirzepatide injection) — Eli Lilly's weight loss formulation
Notably absent: Ozempic (approved for diabetes, not obesity), Mounjaro (same — diabetes indication only), and all compounded versions of semaglutide or tirzepatide. Medicare does not cover compounded medications under this program.
Who Qualifies
Eligibility requirements are straightforward but specific:
- BMI of 35 or higher: Automatic qualification
- BMI of 30-34.9: Must have at least one weight-related comorbidity (type 2 diabetes, cardiovascular disease, obstructive sleep apnea, etc.)
- Already on a GLP-1: If you started before July 2026 and met the BMI criteria at treatment initiation, you qualify even if you've since lost weight below the threshold
You must be enrolled in a Medicare Part D prescription drug plan — either a standalone PDP or through a Medicare Advantage plan (MA-PD) that includes drug coverage. Prior authorization is required, and your prescriber will need to attest to your BMI status.
What It Costs
The headline number: $50 per month for a monthly supply. Anti-obesity medications under the Bridge program are exempt from the Part D deductible, meaning you pay the flat copay from day one without needing to meet a spending threshold first.
Compare this to the alternatives: brand-name Wegovy without insurance runs $1,350+ per month. Even with manufacturer savings cards (which Medicare beneficiaries historically couldn't use), the out-of-pocket burden was prohibitive for most seniors on fixed incomes.
How Telehealth Fits In
Here's where it gets relevant to your provider decision: many telehealth platforms are adding Medicare-compatible prescribing pathways specifically for the Bridge launch. The platforms that already work with commercial insurance are best positioned to handle Medicare billing.
When evaluating telehealth providers for Medicare GLP-1 access, prioritize those that explicitly confirm Medicare Part D billing capability, handle prior authorization on your behalf, and have established pharmacy partnerships that accept Medicare.
What the Bridge Doesn't Cover
Some important limitations to understand before you enroll:
- No compounded medications: Only FDA-approved brand-name products qualify
- No off-label prescribing: Ozempic for weight loss is not covered (only its diabetes indication is)
- Temporary program: Coverage runs through December 31, 2027. What happens after that depends on whether CMS implements the BALANCE Model or Congress passes permanent coverage legislation
- Formulary variation: Individual Part D plans have some flexibility in which medications they list and what prior authorization requirements they impose
The Bigger Picture
The Medicare GLP-1 Bridge is historic not just because of what it covers, but because of what it signals. Medicare spent $27.5 billion on GLP-1 medications in 2024 — almost entirely for diabetes indications. The Bridge adds obesity as a covered use, acknowledging what clinical evidence has demonstrated for years: obesity is a chronic disease that responds to pharmacological treatment.
At the same time, only 13 states provide Medicaid coverage for GLP-1 obesity treatment — down from 16 in 2025 — meaning the access gap for lower-income Americans outside Medicare is actually widening even as Medicare access expands.
If you're a Medicare beneficiary who's been watching the GLP-1 conversation from the sidelines because of cost, July 1, 2026 is your date. Talk to your prescriber, confirm your Part D plan's formulary, and ask about prior authorization requirements now so you're ready when the program goes live.